Status:
COMPLETED
London's Exogenous Surfactant Study for COVID19
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborating Sponsors:
London Health Sciences Centre
Conditions:
ARDS, Human
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The research team is investigating administering exogenous surfactant in COVID-19 patients with ARDS. The overall goal is to improve the outcome (mortality) of mechanically ventilated COVID-19 patient...
Detailed Description
The most severe patients infected by the virus that causes COVID-19 develop severe respiratory failure (called ARDS) and require mechanical ventilation in the intensive care unit to help maintain oxyg...
Eligibility Criteria
Inclusion
- age over 18 years
- definitive proof of COVID-19 infection within 48 hours of intubation
- acute respiratory failure with PaO2/FiO2 \< 300 requiring intubation
Exclusion
- known or high suspicion of pre-existing heart failure, unstable angina
- presence of severe shock with hemodynamic instability despite escalating vasopressors
- severe, underlying lung disease (COPD, pulmonary fibrosis, lung cancer. etc.)
- Concurrent treatments are delivered directly into the lung (ie anesthetics etc)
- Diagnosis of pulmonary hemorrhage
Key Trial Info
Start Date :
November 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 6 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04375735
Start Date
November 23 2020
End Date
October 6 2021
Last Update
November 11 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
London Health Sciences Centre - University Hospital
London, Ontario, Canada, N6A 5A5
2
Victoria Hospital
London, Ontario, Canada